home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  October 16, 2018
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[1] [3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 553 active entries


Friesenstr. 36
D-26721 Emden

Phone: +49 (4921) 99-33-6 -0
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it


PharmaInformatic is a German biotech company, which provides ADME/Tox Knowledge Bases and predictive tools (Expert Systems) to improve drug discovery and development. The company was founded in 2004 by Dr. Wolfgang Boomgaarden and is based in Emden, Germany. PharmaInformatic has developed PACT-F, the largest and most annotated knowledge base on bioavailability of drugs worldwide.


Knowledge Bases:

PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability) contains experimental bioavailability results of clinical trials in humans and preclinical trials in animals. The results and conditions of those trials have been taken manually from reliable scientific publications. PACT-F contains the knowledge from more than 5000 scientific research articles related to bioavailability.

The development of PACT-F commenced in 2005. PACT-F is now the largest knowledge base on bioavailability worldwide. It contains 8296 records, which are extensively annotated: up to 17 fields describe in detail the results and conditions of a trial.

Every record contains the investigated chemical structure. This enables scientists to build relationships between structures and properties and to select drug candidates with sufficient oral bioavailability for human clinical trials. The knowledge base has been used to develop models which estimate oral bioavailability in humans much more precisely than animal trials.


PACT-F is the fundamental knowledge base to analyse the factors and conditions which influence bioavailability. It provides scientists with the results and knowledge of 100 years of bioavailability research in order to improve future drug design and drug development.

The expert system IMPACT-F which calculates oral bioavailability of novel drug candidates is based of the knowledge of PACT-F.



For further information on oral bioavailability of blockbuster drugs in humans and animals, see




Expert Systems:

PharmaInformatic´s expert systems help to identify and prioritise promising drug candidates for clinical trials in humans. Our products select compounds which display a high probability of becoming a successful drug:

Prediction of oral bioavailability in humans


The expert system IMPACT-F predicts the oral bioavailability of novel drugs in humans. The calculation is based on reliable computational models, which have been derived from the largest knowledge base on bioavailability worldwide (PACT-F).

It is easy to use, it requires no chemical synthesis or animal experiments, it is much more reliable and cheaper than animal trials and results are almost immediately available. 

IMPACT-F calculates human oral bioavailability much more precisely compared to animal trials. Bioavailability predictions of IMPACT-F were as accurate as the common deviation between individual humans taking part in the same clinical trial.


Read current research results on bioavailability of drugs:


helps to identify and prioritise promising drug candidates with the maximum possibility of success in human trials. The expert system is based on a variety of reliable models. Extremely large structure-activity relationships (SAR) with up to hundreds of thousands compounds allow the estimation of useful drug-like chemical space. Structure-property relationships (SPR) which are derived from PharmaInformatic´s large in-house ADME/Tox-database can be applied to predict ADMET properties and to identify potential risks in order to reduce clinical failures.


detects antibacterial drug candidates. The expert system identifies novel antibiotic substances at the earliest stage through analysing the chemical structure of a drug candidate, its ADME characteristics and its molecular targets.


detects antiviral drug candidates. The expert system combines different strategies of drug research, so that structural patterns of virus-specific and target-specific inhibitors will be recognised.


Further information:www.pharmainformatic.com/html/products.html


PharmaInformatic, Friesenstr. 36, 26721 Emden, Germany

Further information: www.pharmainformatic.com

Keywords: PACT-F, Oral Bioavailability, ADME/Tox, Drug Discovery, ChemInformatics, Compound Selection, Lead Prioritisation, Blockbuster Drugs, Top selling drugs

Selection of drug candidates for clinical trials in humans: IMPACT-F


Lead Optimization and selection of a drug-candidate


Read current Press Release:
Artificial Intelligence optimizes discovery of future drugs (pdf)


Unsere Forschung und Technologie ersetzt Tierversuche.

Unterstütze unsere Arbeit gegen Tierversuche mit nur einem Klick!




Selected Categories:
Product Company   Service Company
- Research
- Research
- Research
- Research
- Software
- Research
- Services

Last update of this entry: January 03, 2017

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2018 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.